

HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HPTN 084 PROTOCOL TEAM MEETING

**Friday, September 29, 2023, 1:30pm – 5:00pm SAST
Grand Ballroom**

Agenda:

- Welcome
- Publications
 - Overall Update
 - Product Choice Presentation
- V5.0 training
 - General Orientation to the V5.0
 - 2 Additional Injections (ONLY if Needed)
 - Updated CAB LA Risk Language
 - Clarified Data to be Collected for non4d Pregnant Women
- Pregnancy Refresher Training
 - Non-4d Pregnant PPTs and Infant Data Collection
 - 4d PPTs and Infant Data Collection
- v5.0 Scenarios
- ViiV Rollover Protocol Discussion
- Full Meeting Close Out

Remaining Time

Closed Meeting for SDMC and LC Discussions